184 related articles for article (PubMed ID: 35498820)
1. Identification and characterization of
Al-Shakliah NS; Attwa MW; Kadi AA; AlRabiah H
RSC Adv; 2020 Apr; 10(28):16231-16244. PubMed ID: 35498820
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of
Al-Shakliah NS; Attwa MW; AlRabiah H; Kadi AA
Anal Methods; 2021 Jan; 13(3):399-410. PubMed ID: 33410830
[TBL] [Abstract][Full Text] [Related]
3. Profiling of
Al-Shakliah NS; Kadi AA; Aljohar HI; AlRabiah H; Attwa MW
RSC Adv; 2022 Jul; 12(32):20991-21003. PubMed ID: 35919181
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Molecules; 2023 May; 28(10):. PubMed ID: 37241965
[TBL] [Abstract][Full Text] [Related]
5.
Alsubi TA; Attwa MW; Bakheit AH; Darwish HW; Abuelizz HA; Kadi AA
RSC Adv; 2020 Jun; 10(38):22668-22683. PubMed ID: 35514564
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS.
Attwa MW; Kadi AA; Darwish HW; Amer SM; Al-Shakliah NS
Chem Cent J; 2018 Sep; 12(1):99. PubMed ID: 30251155
[TBL] [Abstract][Full Text] [Related]
7. Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS:
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Heliyon; 2023 Jun; 9(6):e17058. PubMed ID: 37484253
[TBL] [Abstract][Full Text] [Related]
8. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.
Abdelhameed AS; Attwa MW; Kadi AA
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762
[TBL] [Abstract][Full Text] [Related]
9. Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study.
Alsubi TA; Attwa MW; Darwish HW; Abuelizz HA; Kadi AA
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1435-1450. PubMed ID: 36738368
[TBL] [Abstract][Full Text] [Related]
10. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2020 Jan; 10(9):5412-5427. PubMed ID: 35498318
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.
Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312
[TBL] [Abstract][Full Text] [Related]
12. Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation.
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
RSC Adv; 2024 May; 14(23):16170-16193. PubMed ID: 38769961
[TBL] [Abstract][Full Text] [Related]
13. LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation.
Attwa MW; Kadi AA; Alrabiah H; Darwish HW
J Pharm Biomed Anal; 2018 Oct; 160():19-30. PubMed ID: 30055343
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.
Abdelhameed AS; Attwa MW; Kadi AA
Drug Des Devel Ther; 2020; 14():5259-5273. PubMed ID: 33299299
[TBL] [Abstract][Full Text] [Related]
15. Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS:
Kadi AA; Darwish HW; Abuelizz HA; Alsubi TA; Attwa MW
R Soc Open Sci; 2019 Jan; 6(1):181714. PubMed ID: 30800400
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites.
Chavan BB; Tiwari S; G S; Nimbalkar RD; Garg P; R S; Talluri MVNK
J Pharm Biomed Anal; 2018 Aug; 157():59-74. PubMed ID: 29772457
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling.
Attwa MW; Kadi AA; Darwish HW; Alrabiah H
Clin Chim Acta; 2018 Jul; 482():84-94. PubMed ID: 29614307
[TBL] [Abstract][Full Text] [Related]
18. LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.
Kadi AA; Attwa MW; Darwish HW
RSC Adv; 2018 Jan; 8(3):1182-1190. PubMed ID: 35540908
[TBL] [Abstract][Full Text] [Related]
19. Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry.
Kadi AA; Amer SM; Darwish HW; Attwa MW
Chem Cent J; 2018 May; 12(1):61. PubMed ID: 29766296
[TBL] [Abstract][Full Text] [Related]
20. Metabolite characterization of ambrisentan, in in vitro and in vivo matrices by UHPLC/QTOF/MS/MS: Detection of glutathione conjugate of epoxide metabolite evidenced by in vitro GSH trapping assay.
Johnsi Rani P; Vishnuvardhan C; Nimbalkar RD; Garg P; Satheeshkumar N
J Pharm Biomed Anal; 2018 Jun; 155():320-328. PubMed ID: 29684813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
